%201.svg)
%201.svg)
The Hidden Cost of Winning: What Talcum Powder Litigation Teaches Contingency Lawyers About Cash Flow
Date:
October 27, 2026
Author:
Roni Dersovitz, Esq.
An active plaintiff's firm can have hundreds of thousands, or even millions, of dollars tied up in marketing and case costs at any given time — capital that is otherwise unavailable for growing the practice or distributing to partners. Contingency fee firms typically front significant costs for marketing, expert witnesses, and other litigation-related expenses long before any payment arrives, and even after a case resolves. Even distributing awards and collecting fees can take considerable additional time.
That structural challenge is manageable when timelines hold. The talcum powder litigation demonstrates what happens when a resolution keeps almost arriving — and doesn't.
The Johnson & Johnson talc litigation is one of the clearest illustrations available of how repeatedly resetting settlement assumptions compounds the cost to the firms carrying the cases.
As of July 2026, more than 90,000 talcum powder lawsuits alleging ovarian cancer or mesothelioma have been filed against companies that made or sold talc products, and 68,435 of those cases remain pending in the federal multidistrict litigation (MDL-2738) in New Jersey.
Rather than moving toward a single resolution, the litigation has cycled through repeated settlement attempts that collapsed before reaching claimants. J&J proposed an $8 billion settlement built around a subsidiary bankruptcy filing; a bankruptcy judge rejected that proposal in 2025. J&J returned with a $6.48 billion proposal routed through a new subsidiary, Red River Talc; a federal judge in Houston dismissed that bankruptcy filing in March 2026, ending that settlement attempt as well. Each collapse reset the clock — not just on resolution, but on every firm that had been carrying case costs against the assumption that a prior version of the deal would hold.
With the bankruptcy route foreclosed for now, the litigation has returned to individual trials. A December 2025 bellwether trial in Los Angeles resulted in a $40 million plaintiff verdict; a subsequent bellwether trial in the same court, decided in July 2026, ended in a defense verdict. That split outcome underscores what firms carrying this portfolio already know: even after more than a decade of litigation, the timeline to resolution — and the amount ultimately recovered — remains genuinely unpredictable case by case.
Firms managing large mass tort portfolios have typically funded those marketing campaigns through credit facilities extended against projected resolution timelines. When a settlement that looked finalized collapses — as it has multiple times in this litigation — those facilities come under pressure at exactly the moment firms had planned to be collecting, not borrowing.
As lenders have grown more cautious around mass tort exposure, traditional credit options for law firms carrying concentrated litigation portfolios have contracted. Lenders increasingly treat contingency receivables tied to unresolved mass torts as speculative, regardless of a firm's historical performance, creating a credit environment where even firms with strong case portfolios can struggle to secure operational financing at the moment they need it most.
The result is a familiar, compounding problem: repeated settlement resets strain credit facilities, restricted credit forces decisions driven by liquidity rather than legal strategy, and the cases that have been in litigation the longest — the ones that should be generating the firm's largest fees — become the source of its greatest financial pressure.
Within every firm managing an extended mass tort portfolio like this one, there is typically a separate pool of matters that have already been resolved, either through a verdict or a direct settlement. Defendants in mass torts even occasionally settle discrete portfolios with individual attorneys outside of an MDL. One example from this same litigation: in 2024, J&J reached a separate $700 million settlement with more than 40 states and Washington, D.C. over talc marketing claims — a matter fully distinct from the ongoing ovarian cancer MDL, already resolved, with terms already set. Roundup is another example: several portfolios settled before the broader MDL resolution.
Settled matters are structurally different from the remainder of an attorney's portfolio. The legal risk is gone. The outcome is confirmed, albeit with some occasional risk as to the injury metrics within a portfolio. What remains is a timing problem: administration of the individual claims, lien resolution, and the mechanics of moving each claim through the process to the point at which it can be disbursed.
That is the specific opportunity that post-settlement/judgment funding addresses, and it is one that most conventional lenders are structurally unable to serve. Personal injury firms operating on contingency face fundamentally different cash flow patterns than corporate firms billing monthly, and most lenders have not built underwriting frameworks that recognize confirmed legal receivables as the distinct assets they are.
Most litigation funders will tell a different story, but the history of the model explains how the industry got here. Litigation finance began with post-settlement advances and case-cost advances. When that pool of opportunities proved too small, the industry moved to advances against specific pending cases. When that model underperformed, the industry moved again, to today's portfolio-based approach. The industry is shifting once more, but one constant remains: no funder can successfully underwrite both duration risk and outcome risk on the same case indefinitely. Until the industry, and the attorneys who rely on it, recognize that limitation, these cycles will repeat — and law firms will keep absorbing the squeeze each time a funder misjudges duration or outcome.
Settled case inventories, however, give law firms a way to break that cycle: a source of liquidity underwritten on time to payment, not on the outcome of a litigation that is still in progress.
Pre-settlement/judgment funding — whether through a litigation funder advancing against pending cases or a credit facility secured against anticipated fee income — carries the full weight of two interdependent uncertainties: whether the case will resolve favorably, and when payment will actually arrive. When both assumptions hold, the economics work. When either breaks, as the talcum powder litigation has now demonstrated across three collapsed settlement structures, the consequences cascade through a firm's financing.
Post-settlement/judgment funding operates on different mechanics entirely. By the time a post-settlement/judgment funder engages, the legal outcome has already been determined. The funder is underwriting time, not merit. For law firms, this means that confirmed settlements or verdicts — even ones still months or years from final distribution — represent a category of asset that can be monetized today, independently of what is happening with the rest of the firm's pending portfolio or its existing credit facility.
The return to the firm is not theoretical future income. It is confirmed earned revenue, accessed earlier than the disbursement process would otherwise allow.
For law firms managing extended mass tort portfolios where credit facilities are under pressure from repeatedly reset timelines, capital solutions built to deliver stable working capital through the final phase of the litigation lifecycle can offer a meaningful lifeline.
For individual settled matters creating cash flow pressure, direct advances against confirmed fees — structured around the specific disbursement timeline of each matter, and underwritten based on the confirmed recovery rather than projected future case outcomes — can provide the working capital needed for sustainability.
The firms that navigate extended litigation timelines most effectively are those that recognize early that settled cases and pending cases are different financial instruments, and that liquidity from confirmed receivables does not have to wait for the rest of a portfolio's administration process to complete.
RD Legal Funding provides tailored capital solutions for law firms by accelerating access to post-settlement/judgment and earned fees. We understand that managing a successful legal practice requires more than just winning cases; it requires strategic financial planning and reliable capital partnerships.
To learn more about strategic options for your practice: Phone: (800) 565-5177 Email: info@legalfunding.com Website: www.legalfunding.com
Roni Dersovitz is the founder and CEO of RD Legal Funding, a pioneer in providing innovative liquidity solutions for contingency law firms, settlement claimants, and legal receivables. With over 25 years of experience in litigation finance, Roni has helped transform legal victories into immediate financial results for thousands of clients. To learn more, visit www.legalfunding.com or contact us at info@legalfunding.com or (800) 565-5177.
Sources: Drugwatch, "Johnson & Johnson Talcum Powder Lawsuit" (July 2026); ConsumerNotice.org, "Talcum Powder Settlement | $8.2 Billion Johnson & Johnson Offer" (2026); LawFirm.com, "Talcum Powder Lawsuit Update" (June 2026); Sokolove Law, "Johnson & Johnson Talcum Powder Lawsuit" and "Talcum Powder Lawsuit Updates & Latest News" (2026); TorHoerman Law, "Johnson & Johnson Talcum Powder Lawsuit Update" (July 2026); United States Judicial Panel on Multidistrict Litigation, MDL-2738 docket records.
.png)